The FDA does not currently have guidelines on microdosing GLP-1 medications and its clear that more study is needed to understand the risks, benefits, and efficacy of doses that are lower than those recommended by current prescription guidelines
Phase 2 trial data (NEJM, 2023) showed mean body weight reductions at higher doses over 48 weeks, but Phase 3 confirmation and long-term safety data are still pending
As a result, GLP-1RAs demonstrate a new therapeutic action in cirrhotic rats with cardiomyopathy through the protective role of HOTAIR via SIRT1 activation [86]
Continuous Support Throughout Your Journey Zealthys support program doesnt just end with securing your medication
reported that human islet amyloid polypeptide inhibited mitochondrial biogenesis, and treatment with exendin-4 partially restored it 10
doi: 10.3892/mmr.2023.13114 18